Optimized HSV-TK Gene for Cancer Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HSV-TK gene therapeutic products are suboptimal for maximal gene expression and tumor kill activity in cancer gene therapy, with limitations in both in vitro and in vivo applications.
Innovation Solution
Optimization of HSV-TK genes through codon optimization, removal of rare codons, correction of splice sites, and modification of nuclear localization sequences to enhance pro-drug activation and viral vector production, resulting in improved enzyme activity and selectivity for cancer cell killing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If wild-type HSV-TK gene is used, then basic thymidine kinase activity is maintained, but gene expression and tumor kill activity are suboptimal
Solution Approach 1:
The patent applies parameter changes by systematically mutating specific amino acid residues (Ala167, Ala168, and their combinations with other residues) in the HSV-TK enzyme to optimize its catalytic properties. These parameter changes in the enzyme's primary structure result in improved gene expression levels and enhanced tumor kill activity while maintaining sufficient thymidine kinase function for prodrug activation.
2Productivity
If amino acid residues 167 and 168 are mutated, then pro-drug activation performance increases, but enzyme structure complexity increases
Solution Approach 1:
The patent applies local quality by making targeted mutations at specific local positions (amino acid residues 167 and 168) within the HSV-TK enzyme structure. These localized changes in the substrate binding domain improve prodrug activation performance without requiring global structural modifications, thus minimizing overall structural complexity while achieving enhanced function.
3Productivity
If codon optimization and splice site correction are performed, then viral vector production increases, but gene sequence complexity increases
Solution Approach 1:
The patent applies preliminary action by pre-optimizing the HSV-TK gene sequence before viral vector construction. Codon optimization and splice site corrections are performed in advance on the gene sequence, ensuring high-level expression and proper processing in mammalian cells. This preliminary optimization of the genetic sequence enables efficient viral vector production and high viral particle titers without requiring complex post-processing modifications.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Nucleic acid sequences encoding improved Herpes Simplex Virus Thymidine Kinases are provided, including their use in diagnostic and therapeutic applications. The thymidine kinases may be mutated using conservative mutations, non-conservative mutations, or both. Also provided are gene therapeutic systems, including viral and retroviral particles.